ANIPANI PHARMACEUTICALS INC
- Analyst Upgrades
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals with a Buy and lowers the price target from $124 to $119. ...
- Analyst Upgrades
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90
Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals with a Hold and lowers the price target from $91 to $90. ...
- GlobeNewswire
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-yearPurified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-yearQuarterly GAAP net income available to common ...
- GlobeNewswire
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August ...
- CNBC
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear. ...
- Analyst Upgrades
Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91
Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals with a Hold rating and announces Price Target of $91. ...
- GlobeNewswire
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the ...
- GlobeNewswire
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 monthsThe most common adverse events reported were consistent ...
- Analyst Upgrades
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target
Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals with a Buy and maintains $124 price target. ...
- GlobeNewswire
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the ...
- GlobeNewswire
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin® Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available to common ...
- GlobeNewswire
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, ...
- GlobeNewswire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic ...
- GlobeNewswire
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI's ...
- GlobeNewswire
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its ...
- GlobeNewswire
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® ...
- GlobeNewswire
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 ...
- GlobeNewswire
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the ...
- GlobeNewswire
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on ...
- Analyst Upgrades
Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $124
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals with a Buy and raises the price target from $115 to $124. ...
- GlobeNewswire
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 ...
- GlobeNewswire
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. ...
- Analyst Upgrades
Barclays Initiates Coverage On ANI Pharmaceuticals with Overweight Rating, Announces Price Target of $100
Barclays analyst Glen Santangelo initiates coverage on ANI Pharmaceuticals with a Overweight rating and announces Price Target of $100. ...
- GlobeNewswire
ANI Pharmaceuticals Announces Formation of "FutureVision Advisory Council" to Help Strategically Guide Ophthalmology and Retina Franchise
PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that it has established The FutureVision Advisory Council to help guide the strategic ...
- GlobeNewswire
ANI Pharmaceuticals Announces Board Transition
Patrick D. Walsh steps down as Chairman and will complete his current term as Board memberThomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board PRINCETON, N.J., Dec. 01, 2025 ...